0820 GMT - The medical technology sector is set for another volatile year in 2025, with investors looking for "safe havens" with less exposure to tariff risks and resilience to macro uncertainty, Berenberg analysts say. Swiss-American Alcon and the U.K's Hikma, who manufacture a large proportion of their products where they are sold, have some degree of pricing power to offset cost inflation as a result of tariffs, the analysts write in a note. Investors' worries center on the risk of a potential U.S. recession due to tariffs that would lead to falling demand for med-techs with significant consumer exposure in the U.S., such as Switzerland's Straumann and Germany's Carl Zeiss Meditec, they say. Despite the market turmoil, investor interest in the sector remains high, the analysts add.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 08, 2025 04:20 ET (08:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。